S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
The How and Why of Investing in Gold Stocks
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
Trump says he took the Fifth in NY civil investigation
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
The How and Why of Investing in Gold Stocks
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
Trump says he took the Fifth in NY civil investigation
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
The How and Why of Investing in Gold Stocks
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
Trump says he took the Fifth in NY civil investigation
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
The How and Why of Investing in Gold Stocks
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
Trump says he took the Fifth in NY civil investigation
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
NYSE:CNMD

CONMED - CNMD Stock Forecast, Price & News

$100.85
+3.45 (+3.54%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$98.17
$100.85
50-Day Range
$88.23
$115.65
52-Week Range
$87.24
$159.11
Volume
307,907 shs
Average Volume
370,097 shs
Market Capitalization
$3.07 billion
P/E Ratio
51.98
Dividend Yield
0.82%
Price Target
$118.33

CONMED MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
17.3% Upside
$118.33 Price Target
Short Interest
Healthy
8.63% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-0.74
Upright™ Environmental Score
News Sentiment
0.12mentions of CONMED in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$1.14 M Sold Last Quarter
Proj. Earnings Growth
15.41%
From $3.70 to $4.27 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

225th out of 1,108 stocks

Electromedical Equipment Industry

5th out of 23 stocks

CNMD stock logo

About CONMED (NYSE:CNMD) Stock

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on CNMD shares. TheStreet cut shares of CONMED from a "b-" rating to a "c+" rating in a research note on Tuesday, June 21st. Piper Sandler cut their price objective on CONMED from $160.00 to $118.00 and set an "overweight" rating for the company in a report on Thursday, July 28th. Stifel Nicolaus cut their price objective on CONMED from $160.00 to $110.00 and set a "buy" rating for the company in a report on Thursday, June 23rd. Finally, Needham & Company LLC cut their price objective on CONMED from $155.00 to $127.00 and set a "buy" rating for the company in a report on Thursday, July 28th. One investment analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $118.33.

CONMED Stock Performance

CONMED stock traded up $3.45 during mid-day trading on Wednesday, hitting $100.85. 315,507 shares of the company's stock traded hands, compared to its average volume of 370,029. The firm has a 50 day simple moving average of $98.36 and a two-hundred day simple moving average of $122.71. CONMED has a fifty-two week low of $87.24 and a fifty-two week high of $159.11. The stock has a market cap of $3.07 billion, a price-to-earnings ratio of 51.96, a P/E/G ratio of 3.19 and a beta of 1.53. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.34 and a quick ratio of 1.16.

CONMED (NYSE:CNMD - Get Rating) last announced its quarterly earnings results on Wednesday, July 27th. The company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.01. CONMED had a return on equity of 13.20% and a net margin of 6.19%. The business had revenue of $277.20 million during the quarter, compared to the consensus estimate of $274.22 million. During the same quarter last year, the firm posted $0.71 EPS. The company's quarterly revenue was up 8.6% on a year-over-year basis. On average, research analysts expect that CONMED will post 3.7 EPS for the current fiscal year.

CONMED Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, July 5th. Stockholders of record on Wednesday, June 15th were issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date of this dividend was Tuesday, June 14th. CONMED's dividend payout ratio is currently 41.24%.

Insider Transactions at CONMED

In other news, CFO Todd W. Garner sold 2,662 shares of CONMED stock in a transaction on Monday, June 13th. The stock was sold at an average price of $99.79, for a total transaction of $265,640.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Todd W. Garner sold 2,662 shares of the firm's stock in a transaction on Monday, June 13th. The stock was sold at an average price of $99.79, for a total value of $265,640.98. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jerome J. Lande sold 6,000 shares of the firm's stock in a transaction on Friday, May 13th. The stock was sold at an average price of $115.42, for a total value of $692,520.00. Following the completion of the transaction, the director now owns 3,928 shares in the company, valued at approximately $453,369.76. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,183 shares of company stock valued at $1,136,118. 1.10% of the stock is currently owned by corporate insiders.

Receive CNMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CONMED and its competitors with MarketBeat's FREE daily newsletter.

CNMD Stock News Headlines

CONMED Completes Acquisition of Biorez, Inc.
KeyCorp Weighs in on CONMED Co.'s Q4 2022 Earnings (NYSE:CNMD)
CONMED (NYSE:CNMD) PT Lowered to $118.00
CONMED (NYSE:CNMD) PT Lowered to $127.00
Conmed (CNMD) Q2 Earnings Meet Estimates
Conmed: Q2 Earnings Snapshot - Greenwich Time
CONMED (CNMD) Set to Announce Earnings on Wednesday
See More Headlines
Receive CNMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CONMED and its competitors with MarketBeat's FREE daily newsletter.

CNMD Company Calendar

Ex-Dividend for 7/5 Dividend
6/14/2022
Dividend Payable
7/05/2022
Last Earnings
7/27/2022
Today
8/11/2022
Next Earnings (Estimated)
10/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Employees
3,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$118.33
High Stock Price Forecast
$127.00
Low Stock Price Forecast
$110.00
Forecasted Upside/Downside
+17.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$62.54 million
Pretax Margin
7.23%

Debt

Sales & Book Value

Annual Sales
$1.01 billion
Cash Flow
$4.30 per share
Book Value
$26.85 per share

Miscellaneous

Free Float
29,087,000
Market Cap
$3.07 billion
Optionable
Optionable
Beta
1.53














CNMD Stock - Frequently Asked Questions

Should I buy or sell CONMED stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CNMD shares.
View CNMD analyst ratings
or view top-rated stocks.

What is CONMED's stock price forecast for 2022?

4 analysts have issued 12 month price objectives for CONMED's shares. Their CNMD share price forecasts range from $110.00 to $127.00. On average, they anticipate the company's share price to reach $118.33 in the next year. This suggests a possible upside of 17.3% from the stock's current price.
View analysts price targets for CNMD
or view top-rated stocks among Wall Street analysts.

How have CNMD shares performed in 2022?

CONMED's stock was trading at $141.76 at the beginning of the year. Since then, CNMD stock has decreased by 28.9% and is now trading at $100.85.
View the best growth stocks for 2022 here
.

Are investors shorting CONMED?

CONMED saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 2,630,000 shares, a drop of 6.1% from the July 15th total of 2,800,000 shares. Based on an average daily volume of 510,800 shares, the days-to-cover ratio is presently 5.1 days.
View CONMED's Short Interest
.

When is CONMED's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our CNMD earnings forecast
.

How were CONMED's earnings last quarter?

CONMED Co. (NYSE:CNMD) posted its earnings results on Wednesday, July, 27th. The company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.01. The business earned $277.20 million during the quarter, compared to the consensus estimate of $274.22 million. CONMED had a trailing twelve-month return on equity of 13.20% and a net margin of 6.19%. The company's revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.71 earnings per share.

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED announced a quarterly dividend on Tuesday, May 24th. Investors of record on Wednesday, June 15th will be given a dividend of $0.20 per share on Tuesday, July 5th. This represents a $0.80 annualized dividend and a yield of 0.79%. The ex-dividend date is Tuesday, June 14th.
Read our dividend analysis for CNMD
.

Is CONMED a good dividend stock?

CONMED (NYSE:CNMD) pays an annual dividend of $0.80 per share and currently has a dividend yield of 0.82%. The dividend payout ratio is 41.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CNMD will have a dividend payout ratio of 18.74% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for CNMD.

What guidance has CONMED issued on next quarter's earnings?

CONMED issued an update on its third quarter 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of $0.78-$0.84 for the period, compared to the consensus earnings per share estimate of $0.92. The company issued revenue guidance of $275.00 million-$290.00 million, compared to the consensus revenue estimate of $284.96 million.

What is CONMED's stock symbol?

CONMED trades on the New York Stock Exchange (NYSE) under the ticker symbol "CNMD."

Who are CONMED's major shareholders?

CONMED's stock is owned by many different retail and institutional investors. Top institutional shareholders include Loomis Sayles & Co. L P (2.54%), Principal Financial Group Inc. (2.33%), Jennison Associates LLC (1.70%), Eagle Asset Management Inc. (1.47%), abrdn plc (1.08%) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.97%). Insiders that own company stock include Barbara J Schwarzentraub, Brian Concannon, Curt R Hartman, Daniel Jonas, Daniel S Jonas, Heather L Cohen, Jerome J Lande, John Jed Kennedy, John L Workman, Johonna Marie Pelletier, Mark E Tryniski, Pat Beyer, Peter K Shagory, Stanley W Peters III, Terence M Berge, Todd W Garner, Todd W Garner and Wilfredo Ruiz-Caban.
View institutional ownership trends
.

How do I buy shares of CONMED?

Shares of CNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CONMED's stock price today?

One share of CNMD stock can currently be purchased for approximately $100.85.

How much money does CONMED make?

CONMED (NYSE:CNMD) has a market capitalization of $3.07 billion and generates $1.01 billion in revenue each year. The company earns $62.54 million in net income (profit) each year or $1.94 on an earnings per share basis.

How many employees does CONMED have?

The company employs 3,800 workers across the globe.

How can I contact CONMED?

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The official website for the company is www.conmed.com. The company can be reached via phone at (727) 392-6464 or via fax at 315-797-0321.

This page (NYSE:CNMD) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.